Skip to main content
. 2016 Oct 12;7(46):75118–75129. doi: 10.18632/oncotarget.12611

Figure 3. MiR-139-5p reverses CD44+/CD133+-associated MDR.

Figure 3

(A) The expression of miR-139-5p in CD44+/CD133+ cells (**p < 0.01). (B) MiR-139-5p expression significantly enhanced the sensitivity of CD44+/CD133+ cells to VCR, L-OHP, 5-FU and Mit, and significantly reduced their IC50 values, based on a CCK-8 assay. (C) The effect of miR-139-5p on the in vitro proliferation of CD44+/CD133+ cells. (D) MiR-139-5p-transfected CD44+/CD133+ cells exhibited enhanced sensitivity towards VCR, L-OHP, 5-FU and Mit, with a greater extent of apoptosis after treatment. (E) Tumors derived from the vector- and miR-139-5p-transfected HCT116 CD44+/CD133+ cells were implanted subcutaneously. The weights of the harvested tumors were measured. Each figure is representative of three independent experiments.